341 related articles for article (PubMed ID: 11336939)
21. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
LeBlanc RP
Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy.
Stewart WC; Stewart JA; Day DG; Sharpe ED; Jenkins JN
Eye (Lond); 2004 Oct; 18(10):990-5. PubMed ID: 15037890
[TBL] [Abstract][Full Text] [Related]
23. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
24. Brimonidine Purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension.
Netland PA; Michael M; Rosner SA; Katzman B; Macy JI
Adv Ther; 2003; 20(1):20-30. PubMed ID: 12772815
[TBL] [Abstract][Full Text] [Related]
25. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination.
Konstas AG; Papapanos P; Tersis I; Houliara D; Stewart WC
Ophthalmology; 2003 Jul; 110(7):1357-60. PubMed ID: 12867391
[TBL] [Abstract][Full Text] [Related]
26. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension.
Day DG; Hollander DA
Curr Med Res Opin; 2008 May; 24(5):1435-42. PubMed ID: 18402717
[TBL] [Abstract][Full Text] [Related]
27. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects.
Konstas AG; Karabatsas CH; Lallos N; Georgiadis N; Kotsimpou A; Stewart JA; Stewart WC
Ophthalmology; 2005 Apr; 112(4):603-8. PubMed ID: 15808251
[TBL] [Abstract][Full Text] [Related]
28. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
[TBL] [Abstract][Full Text] [Related]
29. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
[TBL] [Abstract][Full Text] [Related]
30. The safety and efficacy of unoprostone 0.15% versus brimonidine 0.2%.
Stewart WC; Stewart JA; Day DG; Jenkins J
Acta Ophthalmol Scand; 2004 Apr; 82(2):161-5. PubMed ID: 15043534
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Whitson JT; Henry C; Hughes B; Lee DA; Terry S; Fechtner RD
J Glaucoma; 2004 Apr; 13(2):168-73. PubMed ID: 15097265
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial.
Lee DA; Gornbein JA
J Glaucoma; 2001 Jun; 10(3):220-6. PubMed ID: 11442187
[TBL] [Abstract][Full Text] [Related]
33. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.
Katz LJ
Am J Ophthalmol; 1999 Jan; 127(1):20-6. PubMed ID: 9932994
[TBL] [Abstract][Full Text] [Related]
34. Additive efficacy of unoprostone isopropyl 0.12% (rescula) to latanoprost 0.005%.
Stewart WC; Sharpe ED; Stewart JA; Holmes KT; Latham KE
Am J Ophthalmol; 2001 Mar; 131(3):339-44. PubMed ID: 11239866
[TBL] [Abstract][Full Text] [Related]
35. Washout periods for brimonidine 0.2% and latanoprost 0.005%.
Stewart WC; Holmes KT; Johnson MA
Am J Ophthalmol; 2001 Jun; 131(6):798-9. PubMed ID: 11384581
[TBL] [Abstract][Full Text] [Related]
36. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
[TBL] [Abstract][Full Text] [Related]
37. Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertension.
Sharpe ED; Henry CJ; Mundorf TK; Day DG; Stewart JA; Jenkins JN; Stewart WC
Eye (Lond); 2005 Jan; 19(1):35-40. PubMed ID: 15094733
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost.
Stewart WC; Day DG; Sharpe ED; Dubiner HB; Holmes KT; Stewart JA
Am J Ophthalmol; 1999 Dec; 128(6):692-6. PubMed ID: 10612504
[TBL] [Abstract][Full Text] [Related]
39. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma.
Konstas AG; Maltezos AC; Gandi S; Hudgins AC; Stewart WC
Am J Ophthalmol; 1999 Jul; 128(1):15-20. PubMed ID: 10482089
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2% and betaxolol 0.25% suspension in patients with open-angle glaucoma and ocular hypertension. Brimonidine Outcomes Study Group II.
Javitt J; Goldberg I
J Glaucoma; 2000 Oct; 9(5):398-408. PubMed ID: 11039742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
